Shares of BeiGene, Ltd. (NASDAQ: BGNE – Get a rating) have been given an average rating of “moderate buy” by the seven rating agencies that currently cover the company, reports MarketBeat Ratings. One analyst rated the stock with a sell rating, one issued a hold rating and five issued a buy rating on the company. The 12-month average target price among brokers who have issued ratings on the stock over the past year is $315.33.
A number of research analysts have published reports on the company. Morgan Stanley raised its price target on BeiGene from $330.00 to $338.00 and gave the company an “overweight” rating in a Tuesday, April 12 research note. StockNews.com downgraded BeiGene from a “hold” rating to a “sell” rating in a Thursday, June 16 research note. Finally, SVB Leerink downgraded BeiGene from an “outperforming” rating to a “market performance” rating and lowered its price target for the stock from $300.00 to $177.00 in a research note. Thursday, March 17.
In other BeiGene news, an Insider Lai Wang sold 445 shares of the company in a transaction dated Friday, June 17. The stock was sold at an average price of $139.40, for a total value of $62,033.00. Following the completion of the transaction, the insider now owns 723 shares of the company, valued at approximately $100,786.20. The sale was disclosed in a filing with the SEC, accessible via the SEC website. Also, CFO Julia Aijun Wang sold 295 shares of the company in a transaction dated Friday, July 1. The stock was sold at an average price of $158.50, for a total value of $46,757.50. Disclosure of this sale can be found here. Insiders sold a total of 14,465 shares of the company valued at $2,229,388 during the last quarter. 8.90% of the shares are held by insiders.
A number of hedge funds and other institutional investors have recently changed their holdings in BGNE. Capital International Investors increased its stake in BeiGene by 11.2% in the 1st quarter. Capital International Investors now owns 7,055,295 shares of the company worth $1,337,378,000 after purchasing an additional 711,396 shares during the period. Bank of America Corp DE increased its stake in BeiGene shares by 77.1% in Q1. Bank of America Corp DE now owns 414,466 shares of the company valued at $78,169,000 after acquiring an additional 180,470 shares last quarter. Bridgewater Associates LP increased its equity stake in BeiGene by 67.3% in Q1. Bridgewater Associates LP now owns 383,818 shares of the company valued at $72,388,000 after acquiring an additional 154,335 shares last quarter. Zeal Asset Management Ltd increased its stake in BeiGene shares by 266.3% in Q1. Zeal Asset Management Ltd now owns 194,838 shares in the company valued at $38,098,000 after acquiring an additional 141,646 shares last quarter. Finally, Capital Group International Inc. CA increased its stake in BeiGene shares by 14.1% in the 1st quarter. Capital Group International Inc. CA now owns 1,140,960 shares of the company valued at $215,185,000 after acquiring an additional 141,133 shares last quarter.
The NASDAQ BGNE opened at $188.74 on Friday. The company has a market capitalization of $19.49 billion, a P/E ratio of -9.39 and a beta of 0.72. The company has a fifty-day simple moving average of $148.31 and a 200-day simple moving average of $188.89. BeiGene has a 12-month low of $118.18 and a 12-month high of $426.56. The company has a current ratio of 5.05, a quick ratio of 4.87 and a debt ratio of 0.03.
BeiGene (NASDAQ: BGNE – Get a rating) last released its quarterly results on Thursday, May 5. The company reported EPS ($4.24) for the quarter, beating analyst consensus estimates of ($4.52) by $0.28. The company posted revenue of $306.60 million in the quarter, compared to analyst estimates of $300.41 million. BeiGene had a negative return on equity of 40.10% and a negative net margin of 218.25%. BeiGene’s revenue decreased by 49.4% compared to the same quarter last year. As a group, sell-side analysts expect BeiGene to post EPS of -15.54 for the current fiscal year.
BeiGene Company Profile (Get a rating)
BeiGene, Ltd., a biotechnology company, focuses on the discovery, development, manufacture and marketing of various drugs globally. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat classic R/R Hodgkin’s lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocytic leukemia and acute myeloid leukemia; XGEVA to treat giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukaemia; KYPROLIS to treat R/R multiple myeloma; SYLVANT to treat idiopathic multicentric Castleman’s disease; QARZIBA to treat neuroblastoma; Pamiparib for the treatment of various solid tumors; and Pobevcy to treat metastatic colorectal cancer, liver cancer and non-small cell lung cancer (NSCLC).
This instant alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]
Should you invest $1,000 in BeiGene right now?
Before you consider BeiGene, you’ll want to hear this.
MarketBeat tracks daily the highest rated and most successful research analysts on Wall Street and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes hold…and BeiGene wasn’t on the list.
Although BeiGene currently has a “moderate buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
See the 5 actions here